Amarin Corporation plc (NASDAQ: AMRN) announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT™ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Amarin Corporation (AMRN) PT Raised to $51 at H.C. Wainwright; REDUCE-IT Update is a 'Home run'November 12, 2018 7:44 AM Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-PoiNovember 10, 2018 3:00 PM Amarin (AMRN): Jefferies Has 'Semi-High Expectations' into AHA, Says Shares Worth Up to $33/Sh in a SaleNovember 8, 2018 7:46 AM